Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Baiyi Biopharmaceutical

Request full access

Therapeutics for episodic and chronic migraine treatment

Hangzhou, ChinaFounded 2021Biotech & Life Sciences

About Baiyi Biopharmaceutical

Baiyi Biopharmaceutical is a biopharmaceutical company established in 2021 and headquartered in Hangzhou, China. The company focuses on the research and development of drugs for difficult-to-treat neurological conditions, specifically targeting episodic and chronic migraines.

The firm operates in the biopharmaceutical sector, concentrating on creating a pipeline of proprietary assets. Its business model is centered on the in-house development of therapeutics. The company's objective is to address the medical needs of patients suffering from neurological diseases by providing new treatment options.

In April 2024, Baiyi Biopharmaceutical secured an undisclosed amount in an angel funding round. The round was led by Transfar and Tailong Investment, with participation from Qinzhi Capital. This investment supports the company's ongoing research and development activities as it advances its drug candidates through the discovery and preclinical stages.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
18.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Drug Development, Neurology, Chronic Disease, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SEED✓Equity / VC Jan 2026 $14M $55M Longpan Investment · SHC Shanghai Biomedical Fund · Hangzhou Capital ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Baiyi Biopharmaceutical in the Hangzhou ecosystem

Live from Dealroom

The Baiyi Biopharmaceutical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

  • Longpan Investment
  • SHC Shanghai Biomedical Fund
  • Hangzhou Capital
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Hangzhou HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Baiyi Biopharmaceutical on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Baiyi Biopharmaceutical’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.